Accelence Announces Venture Partnership With PharmaNest to Support US Commercialization
Accelence is pleased to announce a partnership with PharmaNest, a contract operations organization marketing breakthrough International IND-Enabling Technologies and Services for the US Markets
PRINCETON, NJ (I-Newswire) August 8, 2012 - Accelence is pleased to announce a partnership with PharmaNest, a contract operations organization marketing breakthrough International IND-Enabling Technologies and Services for the US Markets.
Accelence fulfills increasing CRO and industry sponsor requirements to boost patient inclusion rates and speed up phase II to phase IV tests, while ensuring compliance with all quality standards. A first in Europe, founded upon a wide-ranging consensus between industrial, hospital and academic environments, Accelence has taken on the following objectives:
- Achieving higher patient inclusion rates in the operation of high-potential industry-sponsored clinical trials;
- Liaising between industry sponsors and investigation sites as a one-stop solution, and streamlining procedures to increase efficiency and reduce leadtime on trials;
- Optimizing patient enrolment by implementation of a practitioners’ network in close collaboration with hospital investigation sites.
“Accelence network of qualified clinical sites and world-renowned Key Opinion Leaders has the capability to help US Pharmaceutical Companies and Clinical research Organization to improve the speed and relevance of clinical trial feasibility studies and, later, execute trials with a focus on quality and effective patient recruitment. Our ecosystems gives access to more than 250,000 patients per year and our expertise is recognized in Oncology, Neurology, Cardiovascular and Orthopedic, with centers of excellence in Medical Devices, Core Lab Imaging, Parkinson’s Disease, Senior Oncology Care” says Patrick Varache, Managing Director of Accelence.
“Accelence brings a solution that most pharmaceutical companies and CROS are seeking, and we are confident that PharmaNest will be the catalyst for several strategic partnerships with leading clinical research industry players in 2013” says Mathieu Petitjean, Ph.D, CEO of PharmaNest.
The team at PharmaNest will be working with Accelence to provide a higher level of visibility of their service offer in North America.
Accelence is a combination of the assets and skills of its 4 founding entities: the BORDEAUX UNIVERSITY HOSPITAL, the BERGONIÉ INSTITUTE (Regional Cancer Center), BORDEAUX SEGALEN UNIVERSITY and the INDUSTRIAL RESEARCH SUPPORT COMPANY (SARI). Founded on the initiative of the Bordeaux Chamber of Commerce and Industry, SARI brings together twelve local SMEs in the relevant sectors (pharmaceuticals, medical devices, nutrition). For industry sponsors and CROs both in France and abroad, Accelence Bordeaux is the solution for easy access to a significant number of potential patients over a wide range of therapeutic fields in clinical trials. For more information, please contact Patrick Varache at pvaracheATaccelence.org
PharmaNest commercializes breakthrough International IND-Enabling Technologies and Services for the More..US Markets. PharmaNest's business model and highly experienced team empower early stage companies to play in high growth market segments, at a fraction of the cost of alternative solutions.Less..
100 Overlook Center, Princeton, NJ
Phone : 609 375 2349
Published in:Science and Research
Published On:August 8, 2012
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
F1000Research Aims to Reduce Publication Bias
Phare Consulting Pushes For Comprehensive Growth In the Security Manufacturing Sector
Differentiated & Focused Conference On Polymeric Materials In Medical Devices Undefined. San Francisco, CA, USA, JUNE 26-28, 2013
Capital Resource Partners Purchases Gamma Medica’s Pre-Clinical Business to Form New Entity, Trifoil Imaging
Well Intervention Market Worth $17.48 Billion By 2018